Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

Candice Cottle-Delisle; Electron Kebebew; Jianhua Yao; Karel Pacak; Naris Nilubol; Paul Meltzer; Roxanne Merkel; Seth M Steinberg; Stephen Marx; Vladimir Neychev

首页> 外文期刊>BMJ Open >Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

【24h】

Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

机译：舒尼替尼或依维莫司的突变靶向治疗在伴或不伴细胞减少手术的胃肠道和胰腺晚期低级或中级神经内分泌肿瘤患者中进行：II期临床试验方案

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《BMJ Open》 |2015年第5期|共页
作者
Candice Cottle-Delisle; Electron Kebebew; Jianhua Yao; Karel Pacak; Naris Nilubol; Paul Meltzer; Roxanne Merkel; Seth M Steinberg; Stephen Marx; Vladimir Neychev;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类临床医学;
关键词

相似文献

外文文献
中文文献

1. Re: "cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase II trial." - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study. [J] . AnsaloniL., DeIacoP., FrigerioL. Gynecologic Oncology: An International Journal . 2012,第1期

机译：回复：“细胞减灭术和腹膜内高温化疗作为晚期上皮性卵巢癌的前期治疗：多机构II期临床试验。” -有关CHORINE研究的一项针对晚期卵巢癌的细胞减灭术和腹膜高温化疗的临床试验的建议。
2. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J] . Pavel Marianne E., Singh Simron, Strosberg Jonathan R., The lancet oncology . 2017,第10期

机译：与高血管内胃肠道或肺神经内分泌肿瘤（Radiant-4）患者的everolimus与安慰剂的健康状生活质量：多期，随机，双盲，安慰剂控制，第3期试验
3. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study [J] . Yao James C., Fazio Nicola, Singh Simron, The Lancet . 2016,第10022期

机译：依维莫司治疗肺或胃肠道的晚期非功能性神经内分泌肿瘤（RADIANT-4）：一项随机，安慰剂对照的3期研究
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial [O] . Vladimir Neychev, Seth M Steinberg, Candice Cottle-Delisle, 2015

机译：舒尼替尼或依维莫司的突变靶向治疗在伴或不伴细胞减少手术的胃肠道和胰腺晚期低级或中级神经内分泌肿瘤患者中进行：II期临床试验方案
6. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial [O] . V. Neychev, S. M. Steinberg, C. Cottle-Delisle, 2015

机译：突变靶向治疗患者在胃肠道和胰腺癌的晚期低级或中间级神经内分泌肿瘤患者中的突变疗法治疗和有或没有细胞团手术的胰腺：II期临床试验的方案

Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

著录项

相似文献

相关主题

期刊订阅